# Siludi Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/siludi-medicine

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Total disclosed funding: $145M
- Latest round: Series A (Oct 9, 2020)
- Investors on record: 4

## About

Based in Shanghai, China, and established in 2017, Siludi Medicine operates as a biopharmaceutical company that focuses on tumor immunotherapy drug development. The company was split from 3D Medicines Corporation due to business development needs. In October 2020, Siludi Medicine raised a series A funding for CNY 970 million from new investors Efung Capital, China Capital Management, Tigermed, and Haide Venture Capital.

Siludi Medicine's main business is the research, development, and commercialization of tumor immunotherapy drugs. Its current pipeline consists of two clinical-stage drug candidates, including KN035, a subcutaneously administered PD-L1 antibody, and 3D-185, a selective FGFR-1/2/3 inhibitor. The KN035 was approved for clinical studies by FDA/NMPA/PMDA in 2017.

The company will use the funding used for product line expansion, clinical trial advancement, industry chain layout, and team recruitment.

## Funding rounds

- Series A, Oct 9, 2020, $145M — Efung Capital, China Capital Management, Tigermed, Haide Venture Capital

## Investors

- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series A
- China Capital Management (https://capitalatlas.ai/funds/china-capital-management) — Series A
- Tigermed (https://capitalatlas.ai/funds/tigermed) — Series A
- Haide Venture Capital — Series A